Stemline Therapeutics (STML +10%) moves up again today after being initiated at Ladenburg Thalmann with a Buy rating and a hefty $36 price target. The stock has been moving steadily higher over the past few weeks, after the FDA granted an Orphan Drug Designation to its treatment for blastic plasmacytoid dendritic cell neoplasm, SL-401.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs